SCHEMBL1967415

SCHEMBL1967415

CN(CCc1ccc2c(c1)OC(F)(F)O2)C1CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SIGMAR1 Q99720 4/20 0.41
CHI3L1 P36222 1/20 0.41
CHIT1 Q13231 1/20 0.41
CHI3L2 Q15782 1/20 0.41
CHIA Q9BZP6 1/20 0.41
CYP19A1 P11511 1/20 0.39
GRIN2B Q13224 2/20 0.39
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
PDE2A O00408 2/20 0.36
SLC6A4 P31645 1/20 0.36
DRD4 P21917 1/20 0.35
KCNJ1 P48048 1/20 0.35
HTR2A P28223 1/20 0.35
FAAH O00519 1/20 0.34
NOS2 P35228 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2403247 0.78 SIGMAR1 (0.52) SIGMAR1CHI3L1CHIT1CHI3L2CHIA
SCHEMBL2405529 0.75 SIGMAR1 (0.44) KDM4EALDH1A1SIGMAR1FAAH
SCHEMBL8367478 0.74 CNR1 (0.40) CYP19A1HCRTR1HCRTR2PDE2ASLC6A4
SCHEMBL22657573 0.72 CTNNB1 (0.41) CYP19A1HCRTR1HCRTR2SLC6A4DRD4
SCHEMBL27044834 0.71 SKP2 (0.42) ALDH1A1CYP19A1SLC6A4FAAH
SCHEMBL1970890 0.71 CHIT1 (0.47) ALDH1A1SIGMAR1CHI3L1CHIT1CHI3L2
SCHEMBL22657669 0.71 CTNNB1 (0.43) KDM4EALDH1A1CYP19A1SLC6A4FAAH
SCHEMBL1969047 0.71 TAAR1 (0.60) SIGMAR1CHI3L1CHIT1CHI3L2CHIA
SCHEMBL1971747 0.71 TAAR1 (0.53) KDM4EALDH1A1CYP19A1SLC6A4DRD4
SCHEMBL2663369 0.70 CTNNB1 (0.41) CYP19A1HCRTR1HCRTR2SLC6A4DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed
EP-2334643-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES Actelion Pharmaceuticals Ltd. (CH) 2011-06-22 EP disclosed
WO-2010044054-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD (CH) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 KDM4E 452/4885ALDH1A1 2292/4885SIGMAR1 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.